- Conditions
- Tuberculosis
- Interventions
- PA-824 200mg, PA-824 50mg
- Drug
- Lead sponsor
- Global Alliance for TB Drug Development
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 778
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
- Interventions
- Antibiotic
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 34
- States / cities
- Los Angeles, California • Jacksonville, Florida • Naples, Florida + 29 more
- Conditions
- Tuberculosis
- Interventions
- Isoniazid, Rifapentine
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 2 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more
- Conditions
- Pneumococcal Vaccines
- Interventions
- 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 45
- States / cities
- Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 32 more
- Conditions
- Anthrax
- Interventions
- BioThrax, AV7909, Sodium chloride injection USP, 0.9% (placebo)
- Biological · Drug
- Lead sponsor
- Biomedical Advanced Research and Development Authority
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Lenexa, Kansas • Mt. Pleasant, South Carolina • Nashville, Tennessee + 1 more
- Conditions
- Staphylococcus Aureus, Health Care Associated Infection, Health Care Worker Patient Transmission
- Interventions
- Swab and decolonization using povidone-iodine cleansing
- Device
- Lead sponsor
- Randy Loftus
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 236 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
- Interventions
- TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet
- Drug
- Lead sponsor
- Global Alliance for TB Drug Development
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
- Interventions
- AP-SA02, Placebo
- Biological · Other
- Lead sponsor
- Armata Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
- Conditions
- Pneumonia, Pneumococcal, Vaccine
- Interventions
- Pneumococcal Vaccine Education
- Behavioral
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Wilkes-Barre, Pennsylvania
- Conditions
- Clostridium Difficile Infection, Diet Modification
- Interventions
- Specific Carbohydrate Diet
- Dietary Supplement
- Lead sponsor
- David Suskind
- Other
- Eligibility
- 18 Months to 21 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Inflammatory Bowel Diseases, Clostridium Difficile Infection
- Interventions
- Fecal Microbiota Transplantation
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Recurrent Clostridioides Difficile Infection
- Interventions
- REC-3964
- Drug
- Lead sponsor
- Recursion Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 115 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Toms River, New Jersey • San Antonio, Texas
- Conditions
- HIV, Pneumococcal Infections, Pneumococcal Vaccines
- Interventions
- PCV-13, PPSV-23
- Biological
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2021
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Denver, Colorado
- Conditions
- Anthrax
- Interventions
- PA83-FhCMB
- Biological
- Lead sponsor
- Fraunhofer, Center for Molecular Biotechnology
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Mycobacterium Infections
- Interventions
- Clofazimine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 100 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bacillus Anthracis (Anthrax)
- Interventions
- Ciprofloxacin 500 mg, ETI-204 (Anthim)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Inflammatory Bowel Diseases, Clostridioides Difficile Infection
- Interventions
- Xylitol, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Tuberculosis
- Interventions
- Epistem Genedrive® and MolBio Truenat™
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Not listed
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Toxic Shock Syndrome Staphylococcal
- Interventions
- Aluminum hydroxide, STEBVax vaccine
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria
- Interventions
- GSK Biologicals'Kinrix®, Merck and Company's MMRII, Merck and Company's Varivax
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 478 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 11
- States / cities
- Antioch, California • Daly City, California • Hayward, California + 7 more
- Conditions
- Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
- Interventions
- Oral Vancomycin, Placebo
- Drug · Other
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Tampa, Florida
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections
- Interventions
- Ethambutol hydrochloride, Clarithromycin, Clofazimine, Rifabutin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1996
- U.S. locations
- 16
- States / cities
- San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- Fecal microbiota
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Months and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin